Drug intelligence / Profile preview

α-Syn H21 monoclonal antibody

Development stage: Phase 1
Lead developer: Mabwell
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

α-Syn H21 is a humanized monoclonal antibody developed by Ruijin Hospital (Shanghai Jiao Tong University School of Medicine) for the treatment of synucleinopathies, specifically Multiple System Atrophy (MSA). The antibody is designed to selectively target and bind to pathological aggregates of alpha-synuclein (α-syn), which are central to the pathogenesis of MSA and Parkinson's disease. By neutralizing these toxic aggregates, α-Syn H21 aims to inhibit their cell-to-cell transmission and reduce associated neuroinflammation, potentially slowing disease progression. It is currently being evaluated in a Phase 1 exploratory clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with MSA.

Other names: alpha-synuclein H21 monoclonal antibody

Targets

Pathological alpha-synuclein fibrilsSNCA (Alpha-synuclein)

Beyond the preview

Go deeper on α-Syn H21 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on α-Syn H21 monoclonal antibody.

Explore the full profile